| Bcl-2 Antiapoptotic Family Proteins and Chemoresistance in Cancer |
31 |
| Advances and Challenges of HDAC Inhibitors in Cancer Therapeutics |
29 |
| Extracellular-Regulated Kinases: Signaling From Ras to ERK Substrates to Control Biological Outcomes |
26 |
| Recent Advances in Nanoparticle-Based Cancer Drug and Gene Delivery |
22 |
| Ceramide and Exosomes: A Novel Target in Cancer Biology and Therapy |
18 |
| VDAC Regulation: A Mitochondrial Target to Stop Cell Proliferation |
16 |
| Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era |
13 |
| Gold Nanoparticles for the Delivery of Cancer Therapeutics |
12 |
| Dormancy and cancer stem cells: An enigma for cancer therapeutic targeting |
11 |
| Exosomes as Theranostics for Lung Cancer |
11 |
| Hypoxia-inducible factors promote breast cancer stem cell specification and maintenance in response to hypoxia or cytotoxic chemotherapy |
10 |
| Mechanisms of Ceramide-Dependent Cancer Cell Death |
10 |
| Ultrasound Contrast Agents and Delivery Systems in Cancer Detection and Therapy |
9 |
| Role of MDA-7/IL-24 a Multifunction Protein in Human Diseases |
9 |
| Acquired Resistance to Drugs Targeting Tyrosine Kinases |
8 |
| Targeting Sphingosine Kinases for the Treatment of Cancer |
7 |
| Interdiction of Sphingolipid Metabolism Revisited: Focus on Prostate Cancer |
7 |
| Regulation of cancer stem cell properties by SIX a member of the PAX-SIX-EYA-DACH network |
7 |
| Thermosensitive Liposomes for Image-Guided Drug Delivery |
7 |
| Immunotherapy in breast cancer: Current status and future directions |
6 |
| Clonal hematopoiesis: Pre-cancer PLUS |
6 |
| Sphingolipids as Regulators of Autophagy and Endocytic Trafficking |
6 |
| Sphingolipids at the Crossroads of NAFLD and Senescence |
6 |
| Pharmacology of ME- a novel cytotoxic isoflavone |
5 |
| Nanotechnology Approaches to Improving Cancer Immunotherapy |
5 |
| From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy |
5 |
| Prospects of Gene Therapy to Treat Melanoma |
4 |
| Evaluation of Resveratrol in Cancer Patients and Experimental Models |
4 |
| PP2A holoenzymes, substrate specificity driving cellular functions and deregulation in cancer |
4 |
| MDA-9/Syntenin: An emerging global molecular target regulating cancer invasion and metastasis |
4 |
| Translation of cancer immunotherapy from the bench to the bedside |
4 |
| Role and Function of Sphingomyelin Biosynthesis in the Development of Cancer |
4 |
| Ceramide Signaling and p53 Pathways |
4 |
| The Role of Ceramide 1-Phosphate in Tumor Cell Survival and Dissemination |
4 |
| Side Effects in Cancer Therapy: Are Sphingolipids to Blame? |
4 |
| Single-Cell Proteomics for Cancer Immunotherapy |
3 |
| The second genome: Effects of the mitochondrial genome on cancer progression |
3 |
| HVEM network signaling in cancer |
3 |
| Neutral Sphingomyelinases in Cancer: Friend or Foe? |
3 |
| A Theoretical Basis for the Efficacy of Cancer Immunotherapy and Immunogenic Tumor Dormancy: The Adaptation Model of Immunity |
3 |
| Immunometabolism: A new target for improving cancer immunotherapy |
3 |
| Expression of costimulatory and inhibitory receptors in FoxP3(+) regulatory T cells within the tumor microenvironment: Implications for combination immunotherapy approaches |
3 |
| Clinical and translational advances in esophageal squamous cell carcinoma |
3 |
| Macroenvironment-gene-microenvironment interactions in ultraviolet radiation-induced melanomagenesis |
2 |
| Cancer stem cells in breast and prostate: Fact or fiction? |
2 |
| Impact of the microbiome on cancer progression and response to anti-cancer therapies |
2 |
| Bittersweet tumor development and progression: Emerging roles of epithelial plasticity glycosylations |
2 |
| The Onus of Sphingolipid Enzymes in Cancer Drug Resistance |
2 |
| Unconventional Approaches to Modulating the Immunogenicity of Tumor Cells |
2 |
| New Insights Into Beclin-1: Evolution and Pan-Malignancy Inhibitor Activity |
2 |
